Macrogenics (NASDAQ:MGNX) Stock, Quote.Headers.trade-ideas

Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Indian,Male,Serious,Doctor,Medical,Worker,In,Modern,Clinic,Wearing

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

INCY

MGNX

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference.

After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial

xr:d:DAFej5iKviI:3,j:1743093025,t:23032907

AROC

CTLP

GRPN

LMND

PINS

SITE

Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

AMD Ryzen

BIMI

DALN

FFIE

FGEN

JTAI

NUZE

PITA

PMEC

POWL

TBIO

TIVC

Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Macrogenics Inc

Press Releases

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Management

MacroGenics Announces Leadership Transition

Earnings

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conference

Legal

MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

APLS

CART

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

C4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Elicio Therapeutics

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Inventiva S.A. - American Depository Shares

Inventiva

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Nanobiotix

Nkarta

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Renovaro

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Citigroup

BMO Capital

Barclays

B. Riley Securities

Comments

Macrogenics

Macrogenics (NASDAQ:MGNX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga